NASDAQ - Aclaris Therapeutics, Inc.

График котировок Aclaris Therapeutics, Inc.

Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 177.06
P/BV 22.13
EV/EBITDA -19.06
EBITDA -0.05
Цена ао 21.02



Название Значение Оценка
P/S 177.06 1
P/BV 22.13 1
P/E 0
EV/EBITDA -19.06 10


Название Значение Оценка
ROA, % -27.72 1
ROE, % -90.46 1


Название Значение Оценка
Div yield, % 0
DSI 0 0


Название Значение Оценка

Импульс роста

Название Значение Оценка
Рост прибыли, % 41.42 8
Рост цены акции, % -89.28 0
Рост дивидендов, % 0 0

Основные владельцы

Institutions Объем Доля, %
Alambic Investment Management, L.P. 59766 0.12
AdvisorShares Investments, LLC 2600 0.01
Samsara BioCapital, LLC 2153265 4.26
Telemetry Investments, L.L.C. 267466 0.53
Foresite Capital Management III, LLC 684912 1.36
Parkman Healthcare Partners LLC 1842661 3.65
Endurant Capital Management LP 1432817 2.84
SEI Investments Management Corp 141371 0.28
BMO Global Asset Management 75944 0.15
Aisling Capital Management LP 634455 1.26
Sofinnova Ventures 1911573 3.78
EcoR1 Capital, LLC 1531312 3.03
BlackRock Fund Advisors 1353400 2.68
Vivo Capital, LLC 1647214 3.26
Rock Springs Capital Management LP 2076307 4.11
LoCorr Fund Management, LLC 3773 0.01
M & G Investment Management 40645 0.08
Invesco Capital Management LLC 121038 0.24
The Variable Annuity Life Insurance Company 119846 0.24
Foresite Capital Management IV, LLC 144874 0.29

Содержится в ETF

ETF Доля, % Доходность за год, %
AdvisorShares Dorsey Wright Micro-Cap ETF 1.51 61.20

Похожие компании

Описание Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK\u002FTXK\u002FJAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.